XML 47 R23.htm IDEA: XBRL DOCUMENT
v3.20.4

Other (Income) Expense, Net | 12 Months Ended
--- | ---
Dec. 31, 2020
Other Income and Expenses [Abstract] |
Other (Income) Expense, Net | Other (Income) Expense, Net Other (income) expense, net, consisted of:
Years Ended December 31 | 2020 |  | 2019 |  | 2018
Interest income | $ | (59) |  |  | $ | (274) |  |  | $ | (343) |
Interest expense | 831 |  |  | 893 |  |  | 772 |
Exchange losses | 145 |  |  | 187 |  |  | 145 |
Income from investments in equity securities, net (1) | (1,338) |  |  | (170) |  |  | (324) |
Net periodic defined benefit plan (credit) cost other than service cost | (339) |  |  | (545) |  |  | (512) |
Other, net | (126) |  |  | 48 |  |  | (140) |
| $ | (886) |  |  | $ | 139 |  |  | $ | (402) |
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. Other, net (as presented in the table above) in 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8). Other, net in 2018 includes a gain of $115 million related to the settlement of certain patent litigation, income of $99 million related to AstraZeneca’s option exercise in 2014 in connection with the termination of the Company’s relationship with AstraZeneca LP (AZLP), and a gain of $85 million resulting from the receipt of a milestone payment for an out-licensed migraine clinical development program. Other, net in 2018 also includes $144 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8), as well as $41 million of charges related to the write-down of assets held for sale to fair value in anticipation of the dissolution of the Company’s joint venture with Supera Farma Laboratorios S.A. in Brazil. Interest paid was $822 million in 2020, $841 million in 2019 and $777 million in 2018.

X
- References No definition available. + Details
Name: | us-gaap_OtherIncomeAndExpensesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -URI http://asc.fasb.org/topic&trid=2122503 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 610 -URI http://asc.fasb.org/topic&trid=49130413 + Details
Name: | us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration